Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction

Steven M. Haffner, Seppo Lehto, Tapani Rönnemaa et al. · New England Journal of Medicine · 1998 · 7.1K citations · Full text

Medicine, Cardiology, Internal Medicine +17

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

Mercedes Ricote, Andrew C. Li, Timothy M. Willson et al. · Nature · 1998 · 3.5K citations

Life Sciences, Cell Biology, Immunology +10

PPAR-γ agonists inhibit production of monocyte inflammatory cytokines

Chengyu Jiang, Adrian T. Ting, Brian Seed · Nature · 1998 · 2.9K citations

Life Sciences, Immunology, Pharmacology +13

Macrophage-specific PPARγ controls alternative activation and improves insulin resistance

Justin I. Odegaard, Roberto R. Ricardo-González, Matthew H. Goforth et al. · Nature · 2007 · 2.1K citations · Full text

Life Sciences, Endocrinology, Molecular Biology +15